Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation

FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.